items on appreciate an us to recap for Thank of XXXX. XXXX important you, today We update you the taking time and occurring join Ioana, afternoon, good a and some in everyone.
on of and partnered support also Over program, advancement the pipeline continued our cell differentiated while for Genentech. our is with the our Roche providing of transplants, to focus lead year, team past which
about excited to have continue to reasons our future. We be many
I OpRegen. will, with as usual, begin
we provided XXXX, had at numerous conducted. I/IIa which program awareness forums updates and we the data we scientific Phase broadened exciting which During from of this trial,
Some Meeting observed by Each such partner, at audience conference, and of collected scientific which medical these and a findings targets I compelling Roche. participate, as we known, during included some analyses Annual widely updates the and ARVO the delivered last Retina certain the new our the and by presentations but Dr. most year, are given the among EU think XXrd one Barak Congress. Adi Annual OpRegen was
and tissue, and provided To complement this updated amount none describe the findings the recovery. sort self of analyses, incapable RPE layers human ELM or that increasing are specifically of beings in At patients which ELM in durable were of are capable retinal genetically of of event, increased RPE detail. inhibitors of the of areas of knowledge, our
right on So unmet of game-changing to we the a believe, dry continue to this massive are approach track for need we potentially AMD. address
with the insights original beyond find parties, were have and investors by to by successful these one speaking because analyses recent exciting myself observations. the ophthalmology and compelling own most more external turning world their are on While the independent by X released confirmed obviously I commercially companies data our when they coming in offer been of original often Lineage
and chance website. I encourage a So if the our to on are detail, you EU you from haven't the they Retina in had so, Congress to review available slides do
at and and Meeting Roche Angiogenesis data releases similarly, recent January. delivered a from Genentech elective presentation Additional in include the
no than their effects observations far time generated note treatment the therapy of Because XX at approaches and event rapid improvements of will which onset can before I its retinal include for diverges independently criticized of all. treatment small to anti-complement XX to which take OpRegen require at treated that to structure from inhibition commonly faster in years complement The detect. effect months insights it patients, is exert meaningfully
complement call third your effects followers consecutive interested the in after after inhibition injections I are a to it, like field consecutive eye. of XX treatment year this into Many of or of as monthly
to who patients a disease should and for that of deterioration those but enjoy actually therapy best For remain long, presumably available on retinal expected committed always progression, of therapy. they structure is vision further slowing even
foveal structure cohort later, for with patients are In were to complement RPE contrast, within months. all suitable inhibition. OpRegen cases, X the showed our always and cases, data after And some in administration of that just detectable patients cells, disease days just in the a severity with from retinal which involvement, comparable they in single patients, improvements X
greater cases, had months were extensive In outer also structure improvements all OpRegen observed cells, over who surgical were time. lesion GA by improvements. patients evidence functional bleb changes anatomical notably, coverage of XX and accompanied containing X RPE most retinal Maintenance in a most at letters. or retinal those the averaging demonstrated in acuity with X improvement gains structure of And visual
average average of acuity among patients above you gain XX gains patients still go And study. of from are who to on are first there visual remaining OpRegen, I'm X.X treated Cohort exhibited long-term on baseline further, after with share months letters, months now XX to the pleased time X for with previously And that with today XX follow-up. the still X.X XX patients Cohort after still evaluable an X [indiscernible]
anatomical Furthermore, with evidence surgical when as slightly the their outer coverage. we higher structure. lesion, associated These of X averaged improvement greater GA expected, or bleb limited those gains patients in extensive to coverage among bleb BCVA BCVA compared no with retinal with the of gains were
in OpRegen of to engraftment patients, OpRegen potential X continues one now earliest one-time extended treated a which for years has treatment. support to to the cells Additionally, the be for RPE evidence
IIa a Phase we and you program. candidate. Roche promising can as is original trial, await as OpRegen, from of So Phase support Genentech's And updates do provide they which study indications interest data can the Genentech provide to evidence the new the therapeutic of which supports conducting, continue see, ongoing I/IIa from and while secondarily
Fortunately, partner XX-month detailed our will we neither be done meeting and providing data, nor medical of to a shared which quarter. held Genentech the of are Roche in updates today just I anticipate second the these in provide Lineage upcoming that and likely kinds an at particular, overview
the data, separate and made were revealed Annual I last from XXXX Meeting addition XX-month today, available. just for functional In abstracts Friday, RFO the publicly
guide of the clinical You development work instrumentation process. and varied a and and preclinical these will delivery there and using and the Roche the surgical to a help from develop methodology. insights into intended are OpRegen survival results engraftment We study present ongoing that plan results see Genentech surgical distribution complement to believe evaluating and are to
program partner's so This study an have well-resourced far not enhance partnering how and more perform this lineage of the as in may and enroll also success this which continues patients. serves our development this position example commitment supplemental trial, to as in ongoing company serves optimization even can evidence of program, as a clinical to to work. of of beyond experienced the with probability further been Therefore, of also a the an Phase IIa
descriptions future through loss. language leading state eliminate and word vision to that degenerative dry textbooks. disease to publications Medical the is from an in OpRegen the and the program, those aim irreversible AMD We irreversible rewrite literally often
which is of our to testing month, our and safety and clearance cord the IND PSD. test program. amendment, delivery new clinical a to enable in called OPCX, initiate of next will of device and important Moving to Last FDA we particular, the announced spinal performance us that clinical OPCX very my milestone, a
provides Geron and conducted on the pioneering other in therapy program work a we know by cells now their with us advantage which company cell a originally studies foundational significant just this how yet As work because, and companies Their will was human don't people. behave are a their by Asterias, reminder, thereafter beginning while acquired.
cumbersome We program, risk. were required a inefficient. Nevertheless, not surgical have method to to patient cells. were years in original administering cells successful studies. which the the to as the as that by OPCX. the made meet The time, into we was for ready it and with required did acquired data cost not cases, itself which our was when turn at counting And washing they process The the the formulation safety plating, too cells, some team knew commercially added while vision complexity, the move later-stage which and we ventilation XX product of the off and and injection candidate delivered by long
Obviously, solution a constraint, create performing on time creates issue. patient, a procedure who not a is to so wanted that for breathing we a
thereafter commercially process solving team viable developed which with OpRegen, deal contributed for for deployed Fortunately, on Roche, the to successfully OPCX. was similar the a changes which same successfully
plating inject For example, formulation, which eliminates developed use immediate the steps. to an washing and they
developing in shared we which team's Our permitted partly invest system. details of new success, us publicly to next have the delivery only a
are struck patients. device system subject the the believe new the device launching. the collaboration will company is through this That system, to trial We developed medical delivery a first we employed superior we we XX which process new in a in the of far which be of with was clinical
OPCX MyPSD easier the and safer the to is and spinal be spinal to is for a The delivery in evaluation the MyPSD. cord dose, thoracic for or study or cells to we for engineering improve simplify oligodendrocyte to develop delivery cord the vivo objective and evaluate our any cervical deliver called patient. of injury, proposed designed or or extensive and sub-acute to Given injury. patients device, efficacy use of chronic surgeon delivery surgical to with safety of MyPSD spinal device system the progenitor experimentation manual conducted perencamal of novel the inject to designed and
which been in device, is during on a any administration. the without among has also patients, will OPCX system opportunity assessments which chronic of OPCX This with functional to patients exciting addition safety to whether administered injury injury, designed the spinal study us investigate all first the to milestone chronic of And efficacy program. be present to deliver be ventilation are new will for and cord we the signals stopping a myPSD performance collecting gives the Importantly, significant be patient patients. cell will this time also
which we few the process, FDA patients activities the protocol in in which for dose Pursuant open opportunities begun anticipate trials. our first occur we study, clinical to SCI IND, are quarter. the clinical to have the There site to participate very next cleared in will recently
part for able of So improve efforts for treatments. it SCI as our with to community, the outcomes reengage are is individuals a no privilege currently which be there to condition, FDA-approved a with to
with excited therapy are achieved even more and by to seek the improvements this trials build upon promising manufactured, how administered. to is And opportunity prepared and results OPCX in in previous we continue to
cell for Institute Regenerative of California CIRM, you Medicine. OPCX recipient therapy of the clinical that awards the first one a was will Some of granted by recall
and surge we OPCX funding goals We an to the have many program program believe last the the But study application seen, of the match medicine, for submitted dose strong led CIRM's of our success month. to with may is a regenerative for has of applications. accelerate you funding development support as CIRM of a
Consequently date with an would applications of the and quite the Directors CIRM last Board Late unexpectedly, January acceptance be announced halting that new they of month, effective of XX.
and is they as was behalf is which of the application so not cycle. reasonably reviewed issues to clinX submitted expected because striving and grant, will programs, any comforted simply of prepare to suggesting are February the to application a has that this address we knowledge, lot course, informed I'm I to CIRM XX, possible clinX am, to Lineage our reopen the way. in but team, pause be a on specific that as on workload Our in not put of to work February in the us our as soon disappointed us
meeting, dose looks the to a already able will be for and will grant X.X cycle. meantime, delay July the study. are believe potentially In start-up to dose the the so, for study the funding simply presumably, reviews review be to restored overall underway. June impact If the be receiving We following quarter activities the enter we
can hopefully time this expect have And things patients simultaneously second so our on we We excellent CIRM, able. and soon monitor novel first to as program. partner enrolling will a for that with as corner, organization that we're we'll with begin site next we open
among The with Related June discuss year, the the on and for symposium, our injury such to challenges leading Investor collaborative the investors, Institute experts, want treatment public launched and development Denari included an as a event advancements update to SCI. analysts Christopher San the which media. AbbVie health expand awareness forum and goals strategies. dialogue members OPCX, newly open efforts the sponsors, collaborative informing I partnerships of Stem our and an to experience persons and we In care also opportunity the at in cord enhancing of innovations, created with Foundation, in presented presented we Cell advocacy CIRM. researchers, SCI UC lived field last This to dual and Diego, Sanford organizations, caregivers, companies you of the spinal
a It are Injury Cord in planning being San Spinal event, XX success a annual in wonderful to which and was currently June is Diego. second and the expanded and stages planned we Investor the for here on be held XX, Symposium, X-day
expect hear can to updates coming on in You this us additional from the months. event
For our be programs, I brief. preclinical will
As functional planned, to with is we address Michigan. animal which are loss, the the cell University ANP program of of subject X, initiating a a of study hearing transplant our collaboration
our assess our into collaboration objectives specific delivery initial to target survive cells after Our whether transplantation. the to evaluate initial from this of areas monitor were and cells engraftment to
to expressing see whether neuronal of wanted markers identity. migrated. cells they the And certain if are We also
the studies. Institute. evidence presented XXth Research And Yash X at Annual successful ANP survival at been of those Michigan month, the University Research the from Kresge last Hearing have for engraftment We of early by Rafael, cells Dr. satisfied in of and with Autolerinology Meeting our Association results were
which Given want the electrical question important we hearing, which X, regions critically the to the of is in brain. early of cells occurs can whether by ask success specific detectable ANP our signaling, measured next and of influence
working are and from closely to Dr. develop we'll we later see them excited be to Rafael what conduct those We models, this learned year. with and
of the editing it today development cell potentially with cell which those to mention today. novel proprietary of process access with vision worthy and purpose creating and and supports in superior because combination technologies of engineering and our provides editing gene important therapies Eterna, extensive is capabilities technology us development with for capitalizing project to cell together the other alliance The our long-term our on a of is
this in to a instance, In certain indication. clinical confer one making candidates. line forward provide look occur advantage to to at programs an immune of are our we that product hypo to time it's premature this initiative, applicable the a at case we details any and working in are but is developmental we which the believe Eterna, iPSC to designed And differentiation reduce of could later us of sharing generate grassroots immunogenicity reach we competitive as the I edit additional least intended year. on milestones, of certain on more this
And my remarks serve today around because a will Jill's as I month. final transition last some to to provide the wanted comments context quick financing we conducted
approximately cash, may you announcement, sheet have X we additional our improves of I or no didn't raise As raised additional provides most quarters runway. elements. our deals Unlike of this the warrants which was seen the have as operating which in deals conducted discount no a seen at-market balance our and at least include year, data release, with financing an other simultaneous structural
the the and favorable as buyers all believe of we two were We didn't were a with of even not because, company, board pay secure issuer. were helped familiar which buyers us of them fee terms holders, for the all banking existing the while members
cost spin-offs, and available my to diversifying conventional proud relied during lowest lineage grants, of during past understood languishing well ways the very equity BD the time out that X raise. new for therapies a It's raise that years expensive, I'm on developing $XX, the seeking wide and tenure, when a of the biotech to out is particular, that our funds, assortment raises was first was in the of years, $XX across at deals, XBI and favor transactions and capital in but ATM
clearly of importance new the shareholder protecting will also view Our never that but interest. is sight rewarding, exciting and of lose we creating medicines is
X to meetings. our advancing the One, only to program for of to key enhancing points summarize for So for not we be Genentech, with extremely continue happy with and scientific and today. OpRegen medical alliance but the also clinic, Roche commitment awareness at through their
for strategic putting to early-stage enrollment a hand our will a Jill our be our of review excited disease from unmet value our and in year a cell into With programs pipeline and enormous validate which I build competition. are program for that, need to limited we we an financials. help can to And look approach. transplant will Two, and ways from call collaborations, advance to continue the with this three, second active
